Bortezomib in Kidney Transplantation | Zendy

Rajeev Raghavan | Zendy; Abdallah Jeroudi | Zendy; Katafan Achkar | Zendy; A. Osama Gaber | Zendy; Samir J. Patel | Zendy; Abdul Abdellatif | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bortezomib in Kidney Transplantation

Author(s) -

Rajeev Raghavan,

Abdallah Jeroudi,

Katafan Achkar,

A. Osama Gaber,

Samir J. Patel,

Abdul Abdellatif

Publication year - 2010

Publication title -

journal of transplantation

Language(s) - English

Resource type - Journals

eISSN - 2090-0015

pISSN - 2090-0007

DOI - 10.1155/2010/698594

Subject(s) - bortezomib , medicine , multiple myeloma , desensitization (medicine) , proteasome inhibitor , plasma cell , transplantation , clinical trial , immunology , oncology , pharmacology , receptor

Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some success, they do not specifically deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies. Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma (a plasma cell neoplasm), induces plasma cell apoptosis. In this paper we review the current body of literature regarding the use of this biological agent in the field of transplantation. Although limited experience with bortezomib may seem to show promise in the realm of transplant recipients desensitization and treatment of AMR, there is also experience that may suggest otherwise. Bortezomib's role in desensitization protocols and treatment of AMR will be defined better as more clinical data and trials become available.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research